VOGX has no valid price this run, blocking any real trade setup; independent of that gap, the engine already flags weak quality, maximum risk, and a speculative binary-biotech classification with zero measurable upside.
Thesis pillars
- Missing Price Data Blocks Trade Setup→Stable
- Risk Score At Maximum Uncertainty→Stable
- Quality Below Floor No Moat→Stable
- +2 more pillars — see the Why tab for full reasoning
VOGENX INC (VOGX) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $17.56, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $55.00 vs price $17.56 — ratio 3.1×). Rejected, falling back to technical TP.; Market cap $260M below $400M minimum.
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human... Read more
Hold if already holding. Not a fresh buy at $17.56, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $55.00 vs price $17.56 — ratio 3.1×). Rejected, falling back to technical TP.; Market cap $260M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $260M below $400M minimum. Not in investable universe. Score 4.1/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-10-10Recent Developments — VOGENX INC
Latest news
- NEWS 12 Health Care Stocks Moving In Thursday's After-Market Session — benzinga Sep 24, 2026
- NEWS 12 Health Care Stocks Moving In Tuesday's Intraday Session — benzinga Sep 22, 2026
- NEWS Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday — benzinga Sep 10, 2026 positive
- NEWS WBB Securities Initiates Coverage On Vogenx with Speculative Buy Rating, Announces Price Target of $42 — benzinga Sep 2, 2026 positive
- NEWS Jones Trading Initiates Coverage On Vogenx with Buy Rating, Announces Price Target of $55 — benzinga Sep 1, 2026 positive
Generated 2026-10-10T11:52:00Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $17.56, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $55.00 vs price $17.56 — ratio 3.1×). Rejected, falling back to technical TP.; Market cap $260M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $260M below $400M minimum. Not in investable universe. Target $37.64 (+114.4%), stop $16.33 (−7.5%), A.R:R 0.0:1. Score 4.1/10, moderate confidence.
Take-profit target: $37.64 (+114.4% upside). Target $37.64 (+114.4%), stop $16.33 (−7.5%), A.R:R 0.0:1. Stop-loss: $16.33.
DATA_ISSUE: analyst_target_implausible (raw $55.00 vs price $17.56 — ratio 3.1×). Rejected, falling back to technical TP.; Market cap $260M below $400M minimum.
VOGENX INC trades at a P/E of N/A (forward N/A). TrendMatrix value score: 5.0/10. Verdict: Hold.
What does VOGENX INC do?Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including...
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.